News from lipocine inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 14, 2022, 08:00 ET LIPOCINE GRANTED US PATENTS DIRECTED TO CNS AND LIVER PROGRAMS

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced that the United States...

Jun 06, 2022, 16:00 ET LIPOCINE ANNOUNCES PRESENTATION AT 2022 EPILEPSY FOUNDATION PIPELINE CONFERENCE

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders,...

May 12, 2022, 08:00 ET Lipocine Announces Positive LPCN 1144 NASH Open Label Extension Study Results

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology to develop innovative products to treat...

May 09, 2022, 08:00 ET Lipocine Announces Financial Results for the First Quarter Ended March 31, 2022

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic disorders, today ...

Apr 11, 2022, 08:00 ET LIPOCINE ANNOUNCES BOARD of DIRECTOR APPOINTMENTS

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, announced today the appointment of Jill...

Mar 29, 2022, 07:05 ET LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA APPROVAL OF TLANDO™

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on developing innovative products for neuroendocrine and metabolic...

Mar 09, 2022, 08:00 ET Lipocine Announces Financial Results for the Year Ended December 31, 2021

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on neuroendocrine and metabolic disorders, today announced financial ...

Mar 01, 2022, 08:00 ET Lipocine Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on neuroendocrine and metabolic disorders, today provided an update...

Feb 03, 2022, 08:00 ET LIPOCINE ANNOUNCES ITS PARTNER RECEIVED FDA ACCEPTANCE OF NDA RESUBMISSION FOR TLANDO®

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on developing innovative products for metabolic and endocrine...

Jan 27, 2022, 08:00 ET Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO®

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the...

Jan 05, 2022, 08:00 ET Lipocine to Present Clinical Data on LPCN 1144 at 2022 NASH-TAG Conference

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that one...

Dec 22, 2021, 08:00 ET LIPOCINE ANNOUNCES PATIENT DOSED IN ITS PHASE 2 STUDY WITH LPCN 1148 FOR MANAGEMENT OF LIVER CIRRHOSIS

Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the first ...

Nov 10, 2021, 08:00 ET Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2021

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial...

Nov 04, 2021, 08:00 ET Lipocine Announces FDA Grants Fast Track Designation to LPCN 1144 for Treatment of Non-Cirrhotic NASH

Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and ...

Nov 01, 2021, 08:00 ET Lipocine Announces Multiple Poster Presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that three...

Oct 18, 2021, 07:00 ET Lipocine And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO®

Under the terms of Agreement Lipocine to receive: Up to $21.0 million in licensing fees, including $11.0 million payable immediately and $10.0...

Oct 05, 2021, 08:00 ET Lipocine to Present at The H.C. Wainwright 5th Annual NASH Investor Conference

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the...

Sep 28, 2021, 08:00 ET Lipocine Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO®

Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the U.S. Food...

Sep 20, 2021, 08:00 ET Lipocine to Present at The Cantor Fitzgerald Virtual Global Healthcare Conference

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the...

Sep 01, 2021, 08:00 ET Lipocine to Present at The H.C. Wainwright 23rd Annual Global Investment Conference

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the...

Aug 25, 2021, 06:30 ET Lipocine's LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endpoint in Phase 2 LiFT Study

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced positive...

Aug 05, 2021, 08:00 ET Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2021

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial...

Jul 14, 2021, 16:00 ET Lipocine Announces Settlement With Clarus Therapeutics

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has...

Jul 06, 2021, 08:00 ET Lipocine To Present At The Ladenburg Thalmann Healthcare Conference

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the...

Jun 23, 2021, 08:00 ET Lipocine Announces Presentations at The International Liver Congress™ 2021 Digital Event

Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical...